CA
NZ
UK
AU
IND
US
NovaBridge Biosciences (NASDAQ:NBP) is a name many investors will not immediately recognize, and understanding it requires knowing its history: the company is the former I-Mab, which transitioned to the NovaBridge Biosciences name and NBP ticker in late 2025 as it repositioned itself as a …
Intelligent Bio Solutions (NASDAQ:INBS), a medical-technology company that makes a fingerprint-based drug-screening system, ticked up after reporting solid revenue growth and margin expansion. For investors, the move raises the question of whether the stock can build further momentum as the company approaches a key …
Cardiff Oncology (NASDAQ:CRDF), a clinical-stage biotechnology company, edged up after reporting strikingly positive mid-stage data for its lead cancer drug. The modest move against a backdrop of encouraging clinical results frames the question of whether this oncology developer can build sustained momentum as it …
ADMABiologics(NASDAQ:ADMA), a maker of plasma-derived biologic therapies, fell despite delivering another quarter of strong profitability and expanding margins. The disconnect between the operating performance and the share price frames the question of whether this profitable, growing specialty biologics company can turn sentiment around.
Alnylam Pharmaceuticals (NASDAQ:ALNY), a leader in RNA interference (RNAi) therapeutics, slipped after the company trimmed its full-year outlook, even as it delivered explosive growth from its flagship medicine. With Wall Street broadly constructive on the name, the question is what could finally reawaken the …
TELA Bio, Inc. (NASDAQ:TELA), a medical-device company specializing in soft-tissue reconstruction and hernia repair, hit a significant setback in the second quarter of 2026, missing estimates and withdrawing its full-year guidance amid headwinds in one of its key markets. The stock slipped as investors …
Medicus Pharma Ltd. (NASDAQ:MDCX), a clinical-stage life-sciences company, has been gaining momentum on the strength of positive data for its lead program, SkinJect, a novel treatment for a common form of skin cancer. The stock has drawn attention as the company advances its dissolvable-microneedle …
Elicio Therapeutics, Inc. (NASDAQ:ELTX), a clinical-stage biotech developing cancer immunotherapies, has been under pressure after its lead program delivered mixed Phase 2 results that forced a strategic rethink. The company is refining its development plan for ELI-002, a therapeuticVaccinetargeting KRAS-mutated cancers, but a limited …
Elutia, Inc. (NASDAQ:ELUT), a medical-device company focused on drug-eluting biomaterial products, has been growing rapidly on the strength of its EluPro antibiotic-eluting envelope for implantable devices, and it recently raisedCapitalto fund a next-generation launch. The stock slipped even as the company delivered robust growth, …
CervoMed Inc. (NASDAQ:CRVO) is a clinical-stage biotech developing neflamapimod, an oral drug for dementia with Lewy bodies, and the company has been generating supportive biomarker and imaging data as it plans a pivotal study. The stock has drawn attention as a potential breakout candidate, …
Please wait processing your request...